Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study | Journal of the American Heart Association
Clinical Practice Guidelines : Kawasaki disease
Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease | Scientific Reports
Kawasaki's Disease - Don't Forget the Bubbles
Recurrent Kawasaki disease and cardiac complications: nationwide surveys in Japan | Archives of Disease in Childhood
Cumulative recurrence rates of Kawasaki disease calculated by different... | Download Scientific Diagram
Abstract 134: Early Immunoglogulin Therapy and Outcomes of Kawasaki Disease | Circulation
Frontiers | Epidemiology of Kawasaki Disease in Europe
Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution | PLOS ONE
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial - The Lancet Child & Adolescent Health
Long-term Consequences of Kawasaki Disease | Circulation
Frontiers | Increased Incidence of Kawasaki Disease in Taiwan in Recent Years: A 15 Years Nationwide Population-Based Cohort Study
Is it Kawasaki Disease or Multisystem Inflammatory Syndrome in Children? - ScienceDirect
Children | Free Full-Text | Recurrent Kawasaki Disease: A Case Report of Three Separate Episodes at >4-Year Intervals
Kawasaki disease recurrence in the COVID-19 era: a systematic review of the literature | Italian Journal of Pediatrics | Full Text
Medicina | Free Full-Text | Clinical Manifestations of Kawasaki Disease at Different Age Spectrum: A Ten-Year Study
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
Kawasaki disease: insights into pathogenesis and approaches to treatment | Nature Reviews Rheumatology
Clinical characteristics of patients with recurrent Kawasaki disease: a nationwide cohort study of 19 456 patients with minimum 3-year follow up | Archives of Disease in Childhood
Frontiers | The Epidemiology and Pathogenesis of Kawasaki Disease
Frontiers | How Should We Classify Kawasaki Disease?
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease | Circulation
Kawasaki disease: pathophysiology and insights from mouse models | Nature Reviews Rheumatology
Children | Free Full-Text | Major Complication Following Kawasaki Disease in an Infant—The Development of Apical Infarction and Aneurysm Formation
Kawasaki Disease: Practice Essentials, Background, Pathophysiology
